Loading…

Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs

•An inactivated whole-virion TBEV vaccine candidate for dogs was developed.•The vaccine candidate was tested in mice and in dogs.•The vaccine was well tolerated and elicited production of neutralizing anti-TBEV antibodies.•Vaccination of mice provided complete protection against lethal TBEV infectio...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2023-10, Vol.41 (42), p.6150-6155
Main Authors: Salat, Jiri, Hunady, Milan, Svoboda, Pavel, Strelcova, Lucie, Strakova, Petra, Fortova, Andrea, Palus, Martin, Ruzek, Daniel
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c403t-71f4f5c0e232d15cbfaa2b9fbb55b5cafef54a72b418cffa5c0f8f05fb3228b53
cites cdi_FETCH-LOGICAL-c403t-71f4f5c0e232d15cbfaa2b9fbb55b5cafef54a72b418cffa5c0f8f05fb3228b53
container_end_page 6155
container_issue 42
container_start_page 6150
container_title Vaccine
container_volume 41
creator Salat, Jiri
Hunady, Milan
Svoboda, Pavel
Strelcova, Lucie
Strakova, Petra
Fortova, Andrea
Palus, Martin
Ruzek, Daniel
description •An inactivated whole-virion TBEV vaccine candidate for dogs was developed.•The vaccine candidate was tested in mice and in dogs.•The vaccine was well tolerated and elicited production of neutralizing anti-TBEV antibodies.•Vaccination of mice provided complete protection against lethal TBEV infection.•Vaccination of dogs prevented the development of viremia after challenge infection. Tick-borne encephalitis (TBE) is a severe neuroinfection of humans. Dogs are also commonly infected with tick-borne encephalitis virus (TBEV). These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this need, a TBEV vaccine candidate for dogs based on inactivated whole virus antigen was developed. The safety, immunogenicity, and efficacy of the vaccine candidate were tested in mice as the preclinical model and in dogs as the target organism. The vaccine was well tolerated in both species and elicited the production of specific anti-TBEV antibodies with virus neutralising activity. Vaccination of mice provided complete protection against the development of fatal TBE. Immunisation of dogs prevented the development of viremia after challenge infection. Therefore, the developed vaccine candidate is promising to protect dogs from severe TBEV infections.
doi_str_mv 10.1016/j.vaccine.2023.09.019
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2865783426</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X23010897</els_id><sourcerecordid>2865783426</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-71f4f5c0e232d15cbfaa2b9fbb55b5cafef54a72b418cffa5c0f8f05fb3228b53</originalsourceid><addsrcrecordid>eNqFkc2LUzEUxYMoWMf5E4SAGzfvefP1PlYiw-gIA24U3IUkL6m3tklN0kL_-0lpV7OZ1V3c3zmXew4hHxj0DNjwedMfjXMYfc-Bix7mHtj8iqzYNIqOKza9Jivgg-wkgz9vybtSNgCgBJtXxN-HgM64EzVxobjbHWJa-4gO64mmQA09-uozRpNP9HqGusbiYqqnZm0wlkorun-dTbktfXR-_9dssWKhGOmS1uU9eRPMtvjb67whv7_d_7p76B5_fv9x9_WxcxJE7UYWZFAOPBd8YcrZYAy3c7BWKaucCT4oaUZuJZtcCKahYQqgghWcT1aJG_Lp4rvP6f_Bl6p3WJzfbk306VC0AAlSSTXCiyifBjVOQvKhoR-foZt0yLE90qgR-DgOUjZKXSiXUynZB73PuGuxaQb63JPe6GuA-tyThlm3npruy0XnWzBH9FkXh-cQF8zeVb0kfMHhCZL3n-Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2870277644</pqid></control><display><type>article</type><title>Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs</title><source>Elsevier</source><creator>Salat, Jiri ; Hunady, Milan ; Svoboda, Pavel ; Strelcova, Lucie ; Strakova, Petra ; Fortova, Andrea ; Palus, Martin ; Ruzek, Daniel</creator><creatorcontrib>Salat, Jiri ; Hunady, Milan ; Svoboda, Pavel ; Strelcova, Lucie ; Strakova, Petra ; Fortova, Andrea ; Palus, Martin ; Ruzek, Daniel</creatorcontrib><description>•An inactivated whole-virion TBEV vaccine candidate for dogs was developed.•The vaccine candidate was tested in mice and in dogs.•The vaccine was well tolerated and elicited production of neutralizing anti-TBEV antibodies.•Vaccination of mice provided complete protection against lethal TBEV infection.•Vaccination of dogs prevented the development of viremia after challenge infection. Tick-borne encephalitis (TBE) is a severe neuroinfection of humans. Dogs are also commonly infected with tick-borne encephalitis virus (TBEV). These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this need, a TBEV vaccine candidate for dogs based on inactivated whole virus antigen was developed. The safety, immunogenicity, and efficacy of the vaccine candidate were tested in mice as the preclinical model and in dogs as the target organism. The vaccine was well tolerated in both species and elicited the production of specific anti-TBEV antibodies with virus neutralising activity. Vaccination of mice provided complete protection against the development of fatal TBE. Immunisation of dogs prevented the development of viremia after challenge infection. Therefore, the developed vaccine candidate is promising to protect dogs from severe TBEV infections.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2023.09.019</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Animals ; Antibodies ; Antigens ; Apathy ; Arachnids ; Bacterial infections ; Dogs ; Effectiveness ; Encephalitis ; Females ; Immunization ; Immunogenicity ; Infections ; Males ; Tick-borne encephalitis ; Tick-borne encephalitis virus ; vaccination ; Vaccine ; Vaccines ; viral antigens ; Viremia ; Viruses</subject><ispartof>Vaccine, 2023-10, Vol.41 (42), p.6150-6155</ispartof><rights>2023 Elsevier Ltd</rights><rights>2023. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-71f4f5c0e232d15cbfaa2b9fbb55b5cafef54a72b418cffa5c0f8f05fb3228b53</citedby><cites>FETCH-LOGICAL-c403t-71f4f5c0e232d15cbfaa2b9fbb55b5cafef54a72b418cffa5c0f8f05fb3228b53</cites><orcidid>0000-0003-4655-2380</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids></links><search><creatorcontrib>Salat, Jiri</creatorcontrib><creatorcontrib>Hunady, Milan</creatorcontrib><creatorcontrib>Svoboda, Pavel</creatorcontrib><creatorcontrib>Strelcova, Lucie</creatorcontrib><creatorcontrib>Strakova, Petra</creatorcontrib><creatorcontrib>Fortova, Andrea</creatorcontrib><creatorcontrib>Palus, Martin</creatorcontrib><creatorcontrib>Ruzek, Daniel</creatorcontrib><title>Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs</title><title>Vaccine</title><description>•An inactivated whole-virion TBEV vaccine candidate for dogs was developed.•The vaccine candidate was tested in mice and in dogs.•The vaccine was well tolerated and elicited production of neutralizing anti-TBEV antibodies.•Vaccination of mice provided complete protection against lethal TBEV infection.•Vaccination of dogs prevented the development of viremia after challenge infection. Tick-borne encephalitis (TBE) is a severe neuroinfection of humans. Dogs are also commonly infected with tick-borne encephalitis virus (TBEV). These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this need, a TBEV vaccine candidate for dogs based on inactivated whole virus antigen was developed. The safety, immunogenicity, and efficacy of the vaccine candidate were tested in mice as the preclinical model and in dogs as the target organism. The vaccine was well tolerated in both species and elicited the production of specific anti-TBEV antibodies with virus neutralising activity. Vaccination of mice provided complete protection against the development of fatal TBE. Immunisation of dogs prevented the development of viremia after challenge infection. Therefore, the developed vaccine candidate is promising to protect dogs from severe TBEV infections.</description><subject>Animals</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Apathy</subject><subject>Arachnids</subject><subject>Bacterial infections</subject><subject>Dogs</subject><subject>Effectiveness</subject><subject>Encephalitis</subject><subject>Females</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Infections</subject><subject>Males</subject><subject>Tick-borne encephalitis</subject><subject>Tick-borne encephalitis virus</subject><subject>vaccination</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>viral antigens</subject><subject>Viremia</subject><subject>Viruses</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkc2LUzEUxYMoWMf5E4SAGzfvefP1PlYiw-gIA24U3IUkL6m3tklN0kL_-0lpV7OZ1V3c3zmXew4hHxj0DNjwedMfjXMYfc-Bix7mHtj8iqzYNIqOKza9Jivgg-wkgz9vybtSNgCgBJtXxN-HgM64EzVxobjbHWJa-4gO64mmQA09-uozRpNP9HqGusbiYqqnZm0wlkorun-dTbktfXR-_9dssWKhGOmS1uU9eRPMtvjb67whv7_d_7p76B5_fv9x9_WxcxJE7UYWZFAOPBd8YcrZYAy3c7BWKaucCT4oaUZuJZtcCKahYQqgghWcT1aJG_Lp4rvP6f_Bl6p3WJzfbk306VC0AAlSSTXCiyifBjVOQvKhoR-foZt0yLE90qgR-DgOUjZKXSiXUynZB73PuGuxaQb63JPe6GuA-tyThlm3npruy0XnWzBH9FkXh-cQF8zeVb0kfMHhCZL3n-Y</recordid><startdate>20231006</startdate><enddate>20231006</enddate><creator>Salat, Jiri</creator><creator>Hunady, Milan</creator><creator>Svoboda, Pavel</creator><creator>Strelcova, Lucie</creator><creator>Strakova, Petra</creator><creator>Fortova, Andrea</creator><creator>Palus, Martin</creator><creator>Ruzek, Daniel</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><orcidid>https://orcid.org/0000-0003-4655-2380</orcidid></search><sort><creationdate>20231006</creationdate><title>Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs</title><author>Salat, Jiri ; Hunady, Milan ; Svoboda, Pavel ; Strelcova, Lucie ; Strakova, Petra ; Fortova, Andrea ; Palus, Martin ; Ruzek, Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-71f4f5c0e232d15cbfaa2b9fbb55b5cafef54a72b418cffa5c0f8f05fb3228b53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Animals</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Apathy</topic><topic>Arachnids</topic><topic>Bacterial infections</topic><topic>Dogs</topic><topic>Effectiveness</topic><topic>Encephalitis</topic><topic>Females</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Infections</topic><topic>Males</topic><topic>Tick-borne encephalitis</topic><topic>Tick-borne encephalitis virus</topic><topic>vaccination</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>viral antigens</topic><topic>Viremia</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salat, Jiri</creatorcontrib><creatorcontrib>Hunady, Milan</creatorcontrib><creatorcontrib>Svoboda, Pavel</creatorcontrib><creatorcontrib>Strelcova, Lucie</creatorcontrib><creatorcontrib>Strakova, Petra</creatorcontrib><creatorcontrib>Fortova, Andrea</creatorcontrib><creatorcontrib>Palus, Martin</creatorcontrib><creatorcontrib>Ruzek, Daniel</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>ProQuest Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library (ProQuest Database)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salat, Jiri</au><au>Hunady, Milan</au><au>Svoboda, Pavel</au><au>Strelcova, Lucie</au><au>Strakova, Petra</au><au>Fortova, Andrea</au><au>Palus, Martin</au><au>Ruzek, Daniel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs</atitle><jtitle>Vaccine</jtitle><date>2023-10-06</date><risdate>2023</risdate><volume>41</volume><issue>42</issue><spage>6150</spage><epage>6155</epage><pages>6150-6155</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•An inactivated whole-virion TBEV vaccine candidate for dogs was developed.•The vaccine candidate was tested in mice and in dogs.•The vaccine was well tolerated and elicited production of neutralizing anti-TBEV antibodies.•Vaccination of mice provided complete protection against lethal TBEV infection.•Vaccination of dogs prevented the development of viremia after challenge infection. Tick-borne encephalitis (TBE) is a severe neuroinfection of humans. Dogs are also commonly infected with tick-borne encephalitis virus (TBEV). These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this need, a TBEV vaccine candidate for dogs based on inactivated whole virus antigen was developed. The safety, immunogenicity, and efficacy of the vaccine candidate were tested in mice as the preclinical model and in dogs as the target organism. The vaccine was well tolerated in both species and elicited the production of specific anti-TBEV antibodies with virus neutralising activity. Vaccination of mice provided complete protection against the development of fatal TBE. Immunisation of dogs prevented the development of viremia after challenge infection. Therefore, the developed vaccine candidate is promising to protect dogs from severe TBEV infections.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><doi>10.1016/j.vaccine.2023.09.019</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-4655-2380</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2023-10, Vol.41 (42), p.6150-6155
issn 0264-410X
1873-2518
language eng
recordid cdi_proquest_miscellaneous_2865783426
source Elsevier
subjects Animals
Antibodies
Antigens
Apathy
Arachnids
Bacterial infections
Dogs
Effectiveness
Encephalitis
Females
Immunization
Immunogenicity
Infections
Males
Tick-borne encephalitis
Tick-borne encephalitis virus
vaccination
Vaccine
Vaccines
viral antigens
Viremia
Viruses
title Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T10%3A41%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20immunogenicity%20of%20a%20veterinary%20vaccine%20candidate%20against%20tick-borne%20encephalitis%20in%20dogs&rft.jtitle=Vaccine&rft.au=Salat,%20Jiri&rft.date=2023-10-06&rft.volume=41&rft.issue=42&rft.spage=6150&rft.epage=6155&rft.pages=6150-6155&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2023.09.019&rft_dat=%3Cproquest_cross%3E2865783426%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c403t-71f4f5c0e232d15cbfaa2b9fbb55b5cafef54a72b418cffa5c0f8f05fb3228b53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2870277644&rft_id=info:pmid/&rfr_iscdi=true